Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
KRAS mutation • ER positive • EGFR mutation • HR positive • BRAF mutation • HER-2 negative
|
Opdivo (nivolumab) • Hiltonol (poly-ICLC) • PNV21 vaccine